Q2 2022 EPS Estimates for Becton, Dickinson and Company Decreased by Analyst (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDXGet Rating) – Stock analysts at SVB Leerink reduced their Q2 2022 earnings estimates for Becton, Dickinson and in a research report issued on Monday, April 18th. SVB Leerink analyst D. Antalffy now forecasts that the medical instruments supplier will post earnings of $3.12 per share for the quarter, down from their prior forecast of $3.15. SVB Leerink has a “Market Perform” rating and a $275.00 price target on the stock. SVB Leerink also issued estimates for Becton, Dickinson and’s FY2022 earnings at $12.87 EPS.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, February 3rd. The medical instruments supplier reported $3.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.86 by $0.78. Becton, Dickinson and had a return on equity of 14.87% and a net margin of 8.75%. The company had revenue of $5 billion during the quarter, compared to analyst estimates of $4.76 billion. During the same period last year, the company posted $4.55 earnings per share. The firm’s quarterly revenue was down 6.0% compared to the same quarter last year.

Other analysts have also issued reports about the company. Morgan Stanley raised their target price on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research note on Monday, April 11th. StockNews.com began coverage on Becton, Dickinson and in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Wells Fargo & Company lifted their price objective on Becton, Dickinson and from $275.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Friday, April 1st. Argus lifted their price objective on Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Finally, Bank of America began coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They set a “neutral” rating on the stock. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and currently has an average rating of “Hold” and an average target price of $276.25.

Shares of NYSE:BDX opened at $263.49 on Wednesday. Becton, Dickinson and has a twelve month low of $235.13 and a twelve month high of $280.62. The firm has a market cap of $75.03 billion, a PE ratio of 45.59, a price-to-earnings-growth ratio of 3.34 and a beta of 0.65. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.78 and a current ratio of 1.23. The business has a fifty day moving average of $266.81 and a 200-day moving average of $255.93.

Institutional investors have recently added to or reduced their stakes in the stock. Accel Wealth Management grew its position in Becton, Dickinson and by 100.0% in the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 50 shares in the last quarter. Sierra Capital LLC grew its position in Becton, Dickinson and by 88.7% in the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter. Level Financial Advisors Inc. bought a new position in Becton, Dickinson and in the fourth quarter valued at $26,000. Icapital Wealth LLC bought a new position in Becton, Dickinson and in the first quarter valued at $31,000. Finally, Rosenberg Matthew Hamilton grew its position in Becton, Dickinson and by 61.5% in the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 48 shares in the last quarter. 84.66% of the stock is owned by institutional investors and hedge funds.

In other news, Director Claire Fraser sold 841 shares of Becton, Dickinson and stock in a transaction dated Tuesday, February 8th. The stock was sold at an average price of $271.70, for a total transaction of $228,499.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Alexandre Conroy sold 6,410 shares of the company’s stock in a transaction that occurred on Thursday, February 3rd. The stock was sold at an average price of $270.16, for a total value of $1,731,725.60. The disclosure for this sale can be found here. Insiders have sold a total of 21,625 shares of company stock worth $5,868,516 in the last quarter. 0.50% of the stock is currently owned by company insiders.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 31st. Stockholders of record on Thursday, March 10th were issued a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a dividend yield of 1.32%. The ex-dividend date was Wednesday, March 9th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 60.21%.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.